October 30, 2015
Astellas Pharma announced on October 29 that it has started a multinational PIII clinical study of its anticancer agent ASP2215 (gilteritinib) in the US. The compound, under investigation for the treatment of relapsed or refractory acute myeloid leukemia (AML), is...read more